《Q1a(R2)_2003_新原料药和新制剂稳定性设计研究(中英文)》由会员分享，可在线阅读，更多相关《Q1a(R2)_2003_新原料药和新制剂稳定性设计研究(中英文)（17页珍藏版）》请在金锄头文库上搜索。
1、.INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USEICH Harmonised Tripartite GuidelineStability Testing of New Drug Substances and ProductsQ1ACurrentStep 4versiondated6 February 2003This Guideline has been developed by the appropriat
2、e ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process. At Step 4 of the Process the final draft is recommended for adoption to the regulatory bodies of the European Union, Japan and USA.ICH指导原则 新药物与新产品稳定性研究Q1AR22003.2.6现行第4版Q1AD
3、ocument HistoryFirst CodificationHistoryDateNew CodificationNovember 2005Q1Approval by the Steering Committee under Step 2 and release for public consultation.16 September 1992Q1Q1AApproval by the Steering Committee under Step 4 and recommendation for adoption to the three ICH regulatory bodies.Q1 w
4、as renamed Q1A.27 October 1993Q1AQ1AApproval by the Steering Committee of the first revision under Step 2 and release for public consultation.7 October 1999Q1AQ1AApproval by the Steering Committee of the first revision under Step 4 and recommendation for adoption to the three ICH regulatory bodies.8
5、 November 2000Q1ACurrent Step 4 versionQ1AApproval by the Steering Committee of the second revision directly under Step 4 without further public consultation, to include consequences of the adoption of Q1F , and recommendation for adoption to the three ICH regulatory bodies.6 February 2003Q1ACover N
6、ote for Revision of Q1AStability Testing of New Drug Substances and Products新药物与新产品稳定性研究Q1AR修正说明The purpose of this note is to outline the changes made in Q1A that result from adoption of ICH Q1F Stability Data Package for Registration Applications in Climatic Zones III and IV. These changes are:本注释
7、的目的是概述R1AR的变化,这些变化是因采纳了ICH Q1F,即在气候带III和IV地区注册申请的稳定性研究要求这一指导原则而产生的,内容包括：1. The intermediate storage condition has been changed from 30C 2C/60% RH 5% RH to 30C 2C/65% RH 5% RH in the following sections:.1 Drug Substance - Storage Conditions - General Case2.2.7.1 Drug Product - Storage Conditions - Ge
8、neral Case2.2.7.3 Drug products packaged in semi-permeable containers3 Glossary - Intermediate testing下列章节中,中间放置环境由302/60%RH5%修正为302/65%RH5%.1 原料药-放置条件-一般情况 .1 制剂-放置条件-一般情况 .3 半渗透容器包装的制剂 3 术语-中间试验 2. 30C 2C/65% RH 5% RH can be a suitable alternative long-term storage condition to 25C 2C/60% RH 5% in
9、 the following sections:.1 Drug Substance - Storage Conditions - General Case.1 Drug Product - Storage Conditions - General Case在下列章节中,302/65%RH5%可作为长期试验放置条件252/60%RH5%的合适替代条件：.1 原料药放置条件 一般情况.1 制剂放置条件 一般情况3. 30C 2C/35% RH 5% RH has been added as a suitable alternative long-term storage condition to
10、25C 2C/40% RH 5% and the corresponding example for the ratio of water-loss rates has been included in the following section:.3 Drug products packaged in semi-permeable containers在下列章节中,302/35%RH5%已作为长期放置条件52/40%RH5%的合适替代条件,相应的计算失水率比值的例子已包括其中：.3半渗透容器包装的制剂Mid-stream switch of the intermediate storage
11、condition from 30C 2C/60% RH 5% RH to 30C 2C/65% RH 5% RH can be appropriate provided that the respective storage conditions and the date of the switch are clearly documented and stated in the registration application.中间放置条件可从302/60%RH5%转为302/65%RH5%,但必须清楚记录转换前后的放置条件和转换日期并在注册申请中阐明。It is recommended
12、that registration applications contain data from complete studies at the intermediate storage condition 30C 2C/65% RH 5% RH, if applicable, by three years after the date of publication of this revised guideline in the respective ICH tripartite region.本修正指南颁布三年内,建议向各ICH机关提交的注册申请内容包括中间放置条件302/65%RH5%的
13、全部试验数据。TABLE OF CONTENTS目录1.INTRODUCTION引言61.1.Objectives of the Guideline目的61.2.Scope of the Guideline 范围61.3.General Principles 通则72.GUIDELINES指导原则72.1.Drug Substance原料药72.1.1.General 通则72.1.2.Stress Testing 影响因素试验72.1.3.Selection of Batches 批的选择82.1.4.Container Closure System包装容器92.1.5.Specificat
14、ion规范92.1.6.Testing Frequency 检测频率92.1.7.Storage Conditions放置条件102.1.8.Stability Commitment 稳定性承诺142.1.9.Evaluation样品评价152.1.10.Statements/Labeling 说明/标签162.2.Drug Product 制剂略163.GLOSSARY 术语174.REFERENCES参考文献略20Stability Testing of New Drug Substances and Products新原料药及新制剂稳定性研究1. INTRODUCTION引言 1.1 O
15、bjectives of the Guideline目的 The following guideline is a revised version of the ICH Q1A guideline and defines the stability data package for a new drug substance or drug product that is sufficient for a registration application within the three regions of the EC, Japan, and the United States. It does not seek necessarily to cover the testing for registration in or e
